FAM225A and hepatocellular carcinoma: LncFAM225A is up-regulated in HCC tissues and sorafenib-resistant HepG2/SOR cells, and inhibition of FAM225A significantly inhibits the resistance of HepG2/SOR cells to sorafenib.